Is Kymera Therapeutics, Inc. (KYMR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.3% / 30% | 7.2% / 30% | 0.0% / 30% | 80.78% / 5% | ✗ NOT HALAL |
| DJIM | 1.3% / 33% | 7.2% / 33% | 0.0% / 33% | 80.78% / 5% | ✗ NOT HALAL |
| MSCI | 9.0% / 33% | 50.0% / 33% | 0.1% / 33% | 80.78% / 5% | ✗ NOT HALAL |
| S&P | 1.3% / 33% | 7.2% / 33% | 0.0% / 33% | 80.78% / 5% | ✗ NOT HALAL |
| FTSE | 9.0% / 33% | 50.0% / 33% | 0.1% / 50% | 80.78% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -3411.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -25.8% | |
| Return on Assets (ROA) | -15.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$233M |
| Free Cash Flow | -$234M |
| Total Debt | $82M |
| Debt-to-Equity | 5.2 |
| Current Ratio | 10.5 |
| Total Assets | $1.7B |
Price & Trading
| Last Close | $80.18 |
| 50-Day MA | $80.00 |
| 200-Day MA | $62.39 |
| Avg Volume | 755K |
| Beta | 2.3 |
|
52-Week Range
$19.45
| |
About Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Kymera Therapeutics, Inc. (KYMR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Kymera Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Kymera Therapeutics, Inc.'s debt ratio?
Kymera Therapeutics, Inc.'s debt ratio is 1.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.0%.
What are Kymera Therapeutics, Inc.'s key financial metrics?
Kymera Therapeutics, Inc. has a market capitalization of $6.4B, and revenue of $39M. Return on equity stands at -25.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.